Candel Therapeutics, Inc. Annual Report: A Deep Dive for Investors

Unlock the insights into Candel Therapeutics, Inc.'s journey in the fight against cancer. This report offers a comprehensive look at the company's performance and strategic direction for the fiscal year that ended on December 31, 2025. We will explore their core business, financial health, key operational achievements, and the significant risks and opportunities shaping their future.

Business Overview: What Does Candel Therapeutics Do?

Candel Therapeutics (Nasdaq: CADL) is a clinical-stage biotechnology company dedicated to developing innovative viral immunotherapies for cancer. They use genetically modified oncolytic viruses – viruses engineered to selectively infect and destroy cancer cells – to stimulate the body's own immune system to fight tumors.

Their primary focus is on advancing two leading drug candidates:

• Aglatimagene besadenovec (CAN-2409): This candidate is currently in Phase 2/3 clinical trials for pancreatic cancer and Phase 2 trials for prostate cancer. It aims to transform tumors into "vaccine factories," training the immune system to recognize and attack the disease.
• Linoserpaturev (formerly CAN-3110): This candidate is in Phase 1/2 clinical trials for high-grade glioma, an aggressive type of brain cancer. It represents a next-generation oncolytic virus platform.

As both a "smaller reporting company" and an "emerging growth company," Candel Therapeutics benefits from reduced public reporting requirements. This status also highlights their earlier stage of development, where their primary focus remains on research and development (R&D) rather than generating significant product revenue.

Financial Performance: The Numbers for Fiscal Year 2025

For the fiscal year ended December 31, 2025, Candel Therapeutics reported the following key financial figures:

• Revenue: The company reported minimal revenue of approximately $0.5 million, primarily from grants or collaboration agreements. This reflects its pre-commercial stage, with revenue remaining largely consistent with the prior fiscal year.
• Net Loss: Candel Therapeutics faced a significant net loss of $75.0 million. This substantial loss is typical for a clinical-stage biotech company heavily investing in R&D and clinical trials. The net loss widened compared to the prior year, mainly due to increased research and development expenses.
• Cash and Cash Equivalents: As of December 31, 2025, the company held approximately $90.0 million in cash, cash equivalents, and marketable securities.
• Cash Burn Rate: The company's operational cash burn (cash used in operating activities) for the year was approximately $65.0 million.

Management Discussion & Analysis Highlights

During 2025, Candel Therapeutics achieved notable progress in its clinical programs:

• CAN-2409: Candel continued enrolling patients in its pivotal pancreatic cancer trial. The company also reported encouraging interim data from its prostate cancer study, suggesting potential effectiveness and a favorable safety profile. Specific data points, such as response rates or survival benefits, were highlighted in investor presentations.
• Linoserpaturev: The Phase 1/2 trial for glioblastoma progressed, with initial safety data showing tolerability. This paves the way for dose escalation and the potential for early efficacy signals.
• Strategic Focus: The company focused its strategy on allocating resources to its lead assets, aiming to achieve key clinical milestones that could attract further funding or partnership opportunities.
• Results of Operations: The increased net loss primarily stemmed from higher research and development expenses, as clinical trials for CAN-2409 and linoserpaturev progressed. This also included increased personnel costs and manufacturing activities. General and administrative expenses also rose due to higher professional fees and public company costs.

Financial Health and Liquidity

As of December 31, 2025, Candel Therapeutics reported approximately $90.0 million in cash, cash equivalents, and marketable securities. Based on its current operational cash burn rate of approximately $65.0 million for the year, the company projects that its existing cash reserves are sufficient to fund operations for roughly 12-18 months, assuming no significant changes in spending or new funding.

The company has outstanding debt obligations, including those under the RTW Purchase Agreement. These agreements include covenants and restrictions that could impact its financial and operational flexibility, requiring the company to meet specific financial and non-financial conditions.

The company's ability to continue as a going concern depends on obtaining additional financing to fund its operations. This financing may include equity offerings, debt financing, or strategic partnerships. Management continually evaluates its capital needs and financing options.

Future Outlook and Strategy

Candel Therapeutics' strategy for the upcoming year remains focused on:

• Advancing Clinical Programs: Prioritizing the progression of CAN-2409 through its pivotal trials and further exploring linoserpaturev's potential. Key operational milestones include continued patient enrollment in ongoing trials and the potential initiation of new clinical studies based on emerging data.
• Capital Management: Prudently managing its existing cash resources while actively exploring options for additional financing, which may include equity offerings, debt financing, or strategic partnerships.
• Partnerships: Actively seeking opportunities for collaborations or licensing agreements to support development and potential commercialization, particularly for later-stage assets or specific indications.
• Regulatory Milestones: The company aims to engage with regulatory authorities to discuss development pathways and potential accelerated approval strategies for its lead candidates.

Management's outlook emphasizes continued investment in its clinical pipeline to achieve critical data readouts.

Competitive Position

The oncology market is highly competitive and rapidly evolving, marked by intense research and development efforts from pharmaceutical and biotechnology companies, academic institutions, and other research organizations. Candel Therapeutics competes with numerous companies developing immunotherapies, gene therapies, and other novel treatments for various cancers, including pancreatic cancer, prostate cancer, and glioblastoma.

Key competitive factors include:

• Efficacy and Safety: A therapy's ability to demonstrate superior effectiveness and a favorable safety profile compared to existing treatments.
• Mechanism of Action: The uniqueness and potential advantages of its viral immunotherapy approach compared to other treatment methods.
• Intellectual Property: The strength and breadth of its patent portfolio protecting its drug candidates and technology.
• Clinical Development Progress: The speed and success of clinical trials and regulatory approvals.
• Commercialization Capabilities: The ability to effectively manufacture, market, and distribute approved products.

Candel Therapeutics believes its oncolytic viral immunotherapy platform, particularly the design of CAN-2409 and linoserpaturev, offers a unique approach to stimulating anti-tumor immunity. However, many competitors possess greater financial, technical, and human resources, along with more extensive experience in clinical development, regulatory affairs, and commercialization.